Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABR + Fruquintinib + Tislelizumab in Metastatic Colorectal Cancer
NCT04948034Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Aug 2021
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib, tislelizumab in colorectal cancer (CRC), sponsored by Fudan University. Status: unknown.
02
Drugs
fruquintinibtislelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04948034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04948034.